



PRESS RELEASE

ASLAN PHARMACEUTICALS FILES FOR PROPOSED INITIAL PUBLIC OFFERING IN THE U.S.

Singapore, 27 March, 2018 – ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its American Depository Shares (ADSs) in the United States.

ASLAN has applied to list its ADSs on The Nasdaq Global Market under the trading symbol “ASLN”. All ADSs to be sold in the offering will be offered by ASLAN. The number of ADSs to be offered, and the price range for the proposed offering have not yet been determined.

Leerink Partners and Piper Jaffray & Co. are acting as joint book-running managers for this offering. BTIG, H.C. Wainwright & Co. and CLSA Limited are acting as co-managers for this offering.

The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525 ext. 6132 or by email at Syndicate@Leerink.com; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicolett Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or via email at prospectus@pjc.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Media and IR contacts

Chris Fang

ASLAN Pharmaceuticals

Tel: +886 2 2758 3333

E-mail: media@aslanpharma.com

Emma Thompson / Stephanie Tan

Spurwing Communications

Tel: +65 6340 7287

Email: ASLAN@spurwingcomms.com

Robert H Uhl

Westwicke Partners

Tel: +1 858 356 5932

Email: robert.uhl@westwicke.com